Alaunos Therapeutics, Inc. · NASDAQ:TCRT
Alaunos Therapeutics — ZIOPHARM Oncology — 34th Annual J.P. Morgan Healthcare Conference (January 2016)
23 slides from Alaunos Therapeutics's conference presentation, Jan 11, 2016
Slide 1: ZIOPHARM 34th Annual J.P. Morgan Healthcare Conference January 2016
Exhibit 99.1 ZIOPHARM 34th Annual J.P. Morgan Healthcare Conference January 2016 ZIOPHARM Oncology
Slide 2: Forward-looking statements
Forward-looking provided “will,” Company’s generally limited trials receptor property Exchange Readers statements process “could,” to: are Trights; by beyond Commission, cell whether todrug cautioned the and reflect (CAR competition Private “expects,” candidates, statements the whether chimericantig
Slide 3: ZIOPHARM: Implementing a unique toolbox
ZIOPHARM: Sleeping ZIOPHARM delivery trial launches of Beauty cytokine (NASDAQ: in Implementing 2016 technology – and T-cell ZIOP) 2017 in-licensed therapy a unique • applying Well–technology capitalized: Non-viral bycombinations ZIOP/XON and toolbox Cash viral inand that enabling Jan delivery equiv
Slide 4: Introduction: Combination Approaches
Introduction: combination Approaches cells T cells T leading Because Multiple cells Ad-RTS-IL-12 tothe immunotherapies combination endogenous +immunotherapy veledimex programming and combination approaches, Administer immunotherapies modified with different immune willmechanisms becells needed to Ad
Slide 5: Ad-RTS-IL-12 + veledimex: Clinical update
Ad-RTS-IL-12 toxicities” during cells the frequency NKfourth cells as expected quarter of Viral + specifically veledimex: Allo-geneic • Looking and promptly stained Clinical for Adverse confirmation cells reversible update* Event multiplied Early upon Grade of increased brain by stopping ? the 3 Ase
Slide 6: Ad-RTS-IL-12 + veledimex: Safety and next steps
Ad-RTS-IL-12 logous rapidly Determine geneic reversible optimal NK + veledimex: upon Tdose cells discontinuation • cells Combination Building Non- Viral upon therapy of Viral veledimex our Auto- with foundation checkpoint •Allo-logous Pattern as the observed inhibitors company geneicin*As –current t
Slide 7: Non-viral platform: Sleeping Beauty
Non-viral into platform: processing lymphocytes •Delivery: •Provides Pathway that Sleeping conduit to canovercome be to of Beauty targeting great regulatory platform value solid in hurdles the tumor “The development Sleeping neo-antigens NK T cells Beauty ofcells personalized using transposon-transp
Slide 8: Sleeping Beauty: Historical CAR-T approaches
Sleeping Beauty: hematopoietic approaches Historical stem-cell First-in-human Controls transplantation Sleeping study NK (HSCT) Beauty CAR•TShowed cells Non- favorable Viral Viral PFS Auto- and OS Allo-logous trends in both geneic autologous Long term andfollow-up allogeneicdata cohorts from •1st No
Slide 9: Sleeping Beauty: Modified design for improved CARs
Sleeping Beauty: Modified improved Sleeping design for Superior Beauty improved data CARpersistence with design next-generation Established and anti-tumor Disease CARsresponse Next-gen Model Bu NoCARs rden T cells Tumor utilizing Modified Combination Sleeping CAR & Beauty mIL-15 of CAR-T demonstrati
Slide 10: Targeting intracellular antigens with TCRs
Targeting surface Approach the T-cell ofproducts intracellular for cellsdeveloping – Presented are antigens: personalized therapies by human The–tokey Targeting leukocyte that toone implementing antigen most antigen TAAs in(HLA) that T-cell willindividual be –therapy Minority via T-cell for patient.
Slide 11: Sleeping Beauty: delivery of TCRs
Sleeping delivery TCRs Cost eliv Beauty: effective Provides Thisapproach conduit non-viral to High approach While costestablished approach is the keyRapid for forCARs, targeting Labortargeting intensive, intracellular solid manufacture tumor antigens viral by slow approaches TCRs manufacture NK TCR
Slide 12: Sleeping Beauty: Farthest advanced non-viral system
Sleeping(SB) Beauty Beauty: transposon Farthest / targeting advancedthe in unique non-viral setclinical of mutations development transposase Nat Med. system 2016 hasJan advanced 6;22(1):26-36. that cause “Success each patient’s for cell-based cancer”immunotherapies farthest in clinical“Presently, de
Slide 13: Viral Delivery: CAR-T for myeloid malignancies
Viral Delivery: expression malignancies Cytotoxicity • Rapidly CAR-T Lentiviral target advancing IFNãproduction CAR Saline T Platform aUntransduced CARSaline T• target Ziopharm Untransduced Tfor cells myeloid isTargeted utilizing Tmalignancies: cells CAR Intrexon’s Targeted T Cells lentiviral • CAR
Slide 14: Viral Delivery: Graft-versus-Host-Disease
Viral cells cells Delivery: Non- Graft-versus-Host-Disease Viral Viral Auto- Allo-logous Ziopharm geneic Infusion is utilizing of lentiviral Tregs withdelivery in vivoand controlled Intrexon’s production proprietary of IL-2 geneGenetic controlmodification technologiesto toexpress modify IL-2 regulat
Slide 15: Natural Killer Cells
Natural cells brain –tumors Build Killeron NK Cells: promising T cells Beyond cells proof-of-principle TNon- cellsViral Natural Viral killer trials Auto- (NK) ongoing Allo-logous cellsat–MDACC Target geneic tumors, infusing e.g., autologous with loss and or mismatch allogeneicofNK HLA cells – Killin
Slide 16: Solving Problems: Switches and manufacturing
Solving Problems: switches Leveraging Generate will large manufacturing address numbers Bio-engineering off-target of T through or effects, NK–and cells MDACC especially bio-processing to produce – CMOs in Tsolid orNK via NK tumors TIntrexon cells cellsContinued with cells Patient-derived retained N
Slide 17: Partnerships: Merck KGaA
Partnerships: nominated granting ($413 upfront/milestones geneic million Merck its With 2per novel KGaA product) Intrexon/Merck forCAR two opt-in in targets T rights development targets; recognizes KGaA during they in will clinical and CAR-T value lead commercial development of IND • CAR Exclusive f
Slide 18: Partnerships: Intrexon and MDACC
Partnerships: modified Cytokinesadoptive (IL-2, WithIL-7, cell Intrexon IL-15, types,and such IL-21 MDACC asand various IL-12) • Fully immune-modulatory ? Chemokines leveraging our NK clinical T strategies cellscollaboration cells driving Non- TViral with cell Viral or MDACC NK Auto- cellto anti-tum
Slide 19: Partnerships: To implement multiple immunotherapies
Partnerships: CAR-T cells CAR-T To implement cells multiple immunotherapies Clinical sites ZIOPHARM MDACC DNA engine • Switches Rapid Clinical Intrexon • CARs Development • TCRs • Cytokines Merck NCI KGaA PBL and IL-12
Slide 20: Addressing unmet medical needs
Addressing approximately 5/100,000 11,090 (Leukemia deaths 52,380 and unmet annually Incidence Lymphoma new medical cases 18,990 4/100,000 needs: Society 14,778 deaths Solid Facts Breast newannually tumors cases 2014-2015, 20,830 annually Refs: andnew hematological Glioblastoma based cases ,090on In
Slide 21: Addressing unmet medical needs: Pipeline
Addressing 3rd AML Modified Generation Combination Bacteria unmet with (microbiome) medical with cytokine Ad-RTS-IL-12 needs: Myeloid GvHD Pipeline malignancies Brain 21 Preclinical Cancertarget Genetically-engineered PhaseUndisclosed I Phase II Ad-RTS-IL-12 MerckTBD Target TCR1GBM Undisclosed Targe
Slide 22: Summary
Summary: as Combination expanding a methodand Multiple toimmunotherapy, genetically unique immunotherapies platform control viral to T control CAR-T, cells and•the combination We and immune are NKlaunching cells system immunotherapies • We multiple are combining immunotherapy are being different adm
Slide 23: ZIOPHARM 34th Annual J.P. Morgan Healthcare Conference
ZIOPHARM 34th Annual J.P. Morgan Healthcare Conference January 2016 ZIOPHARM Oncology
ZIOPHARM Oncology — 34th Annual J.P. Morgan Healthcare Conference (January 2016) on 6ix